Back to News
Market Impact: 0.25
Eton Licenses LIBERVANT For U.S. Seizure Rescue Market
Source: Nasdaq
Healthcare & BiotechProduct Launches
Eton Pharmaceuticals and Aquestive Therapeutics entered an exclusive U.S. licensing and supply agreement for LIBERVANT, described as a cheek-administered seizure rescue therapy. The article says it could provide patients and caregivers another treatment option; it gives no financial terms or launch timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
AQST0.40
ETON0.40
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Razer’s CEO waited 20 years for everyone to become a gamer. He says AI is finally making it happen
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Tech giants race to get AI gadgets on shelves for holiday rush
- Electric vehicle sales in the U.S. are showing signs of life
- Delta knows the top 40% of Americans are $40 trillion richer than just a few years ago. Cue new burgers and bourbon on Delta One’s biggest revamp yet